Kinexus Bioinformatics Corporation, Vancouver, Canada.
Semin Cell Dev Biol. 2012 Oct;23(8):872-82. doi: 10.1016/j.semcdb.2012.05.009. Epub 2012 Jun 15.
Unraveling the complexity of cell regulatory systems and monitoring their operations under normal and pathological circumstances is one of the major outstanding biomedical challenges. The phosphoproteome has emerged as a rich source of biomarkers for tracking cell signaling and disease, and many of the kinases that phosphorylate proteins represent attractive targets for drug development. Over 100,000 phosphorylation sites distributed in most of the 23,000 proteins encoded by the human genome have already been identified in a non-targeted fashion by mass-spectrometry. Antibody microarrays permit ultra-sensitive, semi-quantitative measurements of the levels of hundreds of target proteins and their phosphorylation in parallel with specimens from cells and tissues. Conversely, reverse-phase protein microarrays (RPPMs) that are printed with crude cell/tissue lysates allow tracking of a target protein with a probing antibody in hundreds to thousands of cell and tissue samples simultaneously. While more than half a million commercial antibodies are available, the identification of highly specific and potent antibodies for use in microarrays remains a major impediment. Antibody cross-reactivity is an issue for both antibody microarrays and RPPMs. The low abundance of signal transduction proteins and their substoichiometric levels of phosphorylation are also problematic. Finally, non-denaturing conditions used with standard antibody microarrays permit protein complexes, which can produce false positives and false negatives. Changes in the level of an interacting protein may be misinterpreted as alterations in the amount of a target protein or its phosphorylation state. It is critical that leads from both types of microarrays are validated by complementary approaches such as immunoblotting and ELISA. More than a hundred reports have appeared in the scientific literature that have benefited from utilization of antibody and protein lysate microarrays. We have highlighted some of the pioneering works in this field and provided recent examples of their successful deployment as tools for broad-based, targeted proteomics research.
阐明细胞调控系统的复杂性,并在正常和病理情况下监测其运作,是当前主要的生物医学挑战之一。磷酸化蛋白质组已成为追踪细胞信号和疾病的生物标志物的丰富来源,许多使蛋白质磷酸化的激酶是药物开发的有吸引力的靶标。通过质谱法已经以非靶向的方式鉴定了分布在人类基因组编码的 23000 多种蛋白质中的超过 100000 个磷酸化位点。抗体微阵列允许超灵敏、半定量地平行测量来自细胞和组织标本的数百种靶标蛋白及其磷酸化水平。相反,用粗细胞/组织裂解物打印的反相蛋白质微阵列(RPPM)可以同时在数百到数千个细胞和组织样本中用探测抗体追踪靶标蛋白。虽然有超过 50 万种商业抗体可用,但用于微阵列的高特异性和有效抗体的鉴定仍然是一个主要障碍。抗体交叉反应性是抗体微阵列和 RPPM 都存在的问题。信号转导蛋白的低丰度及其亚化学计量水平的磷酸化也是一个问题。最后,标准抗体微阵列中使用的非变性条件允许蛋白质复合物产生,这可能会产生假阳性和假阴性。相互作用蛋白水平的变化可能被误解为靶标蛋白或其磷酸化状态的量的改变。至关重要的是,来自这两种微阵列的线索都需要通过免疫印迹和 ELISA 等互补方法进行验证。已经有一百多个报告在科学文献中出现,这些报告受益于抗体和蛋白质裂解物微阵列的使用。我们突出了该领域的一些开创性工作,并提供了最近成功将其作为广泛靶向蛋白质组学研究工具部署的例子。